GlassScriptPhysician profile
Lawrence Kelly
NPI 1629031901
$40,766.27
in general payments reported to CMS, 2019-2025
28 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $13K · 2021: $3,610 · 2022: $1,218 · 2023: $1,459 · 2024: $1,104 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,456 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.53 |
| Education | $186.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35,808.80 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,396.03 | 2021-2025 | |
| Lundbeck LLC | $548.49 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $460.75 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $441.93 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.99 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $347.69 | 2019-2025 | Trintellix |
| Allergan, INC. | $268.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $139.81 | 2019 | |
| Eisai INC. | $136.86 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $110.57 | 2019-2025 | Fanapt, Hetlioz |
| Amgen INC. | $99.40 | 2019 | |
| Avanir Pharmaceuticals, INC. | $87.69 | 2020-2022 | |
| Mdd US Operations, LLC | $84.56 | 2019 | |
| Corium, LLC | $52.95 | 2022-2024 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $50.53 | 2025 | |
| Shire North American Group INC | $44.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $35.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $32.23 | 2019-2021 | |
| Alkermes, INC. | $29.40 | 2024 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $20.16 | 2022 | |
| Pfizer INC. | $16.93 | 2023 | |
| Bausch Health US, LLC | $15.99 | 2019 | |
| Neos Therapeutics, LP | $15.70 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.46 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.58 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.